<DOC>
	<DOCNO>NCT02513186</DOCNO>
	<brief_summary>Primary Objective : To determine maximum tolerate dose ( MTD ) recommend dose ( RD ) isatuximab administer combination bortezomib , cyclophosphamide , dexamethasone base dose-limiting toxicity ( y ) ( DLTs ) observe patient newly diagnose MM non-eligible transplantation . Secondary Objectives : - To characterize overall safety profile isatuximab combination bortezomib , cyclophosphamide , dexamethasone , include cumulative toxicity . - To characterize pharmacokinetic ( PK ) profile isatuximab combination component . - To evaluate immunogenicity isatuximab combination treatment . - To evaluate preliminary antitumoral activity combination .</brief_summary>
	<brief_title>SAR650984 ( Isatuximab ) Combined CyBorD Newly Diagnosed Multiple Myeloma ( MM ) Non Eligible Transplant</brief_title>
	<detailed_description>The duration study individual patient include period assess eligibility ( screen baseline period ) 3 week , treatment period include 12 induction treatment cycle ( 50-week duration ) , follow maintenance period 4-week cycle end-of-treatment visit least 30 day follow last administration treatment ( patient receive another anticancer therapy , whichever early ) . Study treatment may continue precluded toxicity , disease progression , death , upon Investigator/patient 's request .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Inclusion criterion : Newly diagnose patient measurable MM define least one following : Serum M protein ≥1 g/dL ( ≥10 g/L ) . Urine M protein ≥200 mg/24 hour . Serum free light chain ( sFLC ) assay : involve FLC assay ≥10 mg/dL ( ≥100 mg/L ) abnormal sFLC ratio ( &lt; 0.26 &gt; 1.65 ) . Patients smolder MM fulfil International Myeloma Working Group criteria eligible . Patients eligible transplant ( age comorbidities Investigator 's discretion ) . Exclusion criterion : Eastern Cooperative Oncology Group performance status &gt; 2 . Poor bone marrow reserve . Poor organ function . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>